期刊
CELL STEM CELL
卷 28, 期 9, 页码 1597-+出版社
CELL PRESS
DOI: 10.1016/j.stem.2021.04.011
关键词
-
资金
- NIH/NIDCR [R01DE029173]
Cancer stem cells (CSCs) evade immune surveillance by upregulating the immune checkpoint molecule CD276, but can be eliminated by anti-CD276 antibodies, inhibiting tumor growth and lymph node metastases. Targeting CD276 may reduce CSCs in head and neck squamous cell carcinoma (HNSCC).
Immunosurveillance is a critical mechanism guarding against tumor development and progression. Checkpoint inhibitors have shown significant success in cancer treatment, but expression of key factors such as PD-L1 in putative cancer stem cell (CSC) populations in squamous cell carcinoma has been inconclusive, suggesting that CSCs may have developed other mechanisms to escape immune surveillance. Here we show that CSCs upregulate the immune checkpoint molecule CD276 (B7-H3) to evade host immune responses. CD276 is highly expressed by CSCs in mouse and human head and neck squamous cell carcinoma (HNSCC) and can be used to prospectively isolate tumorigenic CSCs. Anti-CD276 antibodies eliminate CSCs in a CD8(+) T cell-dependent manner, inhibiting tumor growth and lymph node metastases in a mouse HNSCC model. Single-cell RNA sequencing (RNA-seq) showed that CD276 blockade remodels SCC heterogeneity and reduces epithelial-mesenchymal transition. These results show that CSCs utilize CD276 for immune escape and suggest that targeting CD276 may reduce CSCs in HNSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据